ERBB2 and breast carcinoma: Furthermore, in preclinical models of HER2-positive breast cancer, 89Zr-ss-pertuzumab exhibited excellent in vivo behavior, in several cases surpassing that of its traditionally synthesized progenitor, stochastically lysine labeled 89Zr-DFO-pertuzumab (16).